PMID- 18404793
OWN - NLM
STAT- MEDLINE
DCOM- 20080624
LR  - 20080411
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 13
IP  - 1
DP  - 2008 Jan-Mar
TI  - Neuron specific enolase tissue expression as a prognostic factor in advanced non 
      small cell lung cancer.
PG  - 93-6
AB  - PURPOSE: To determine the frequency of neuron specific enolase (NSE) tissue 
      expression and its possible influence on survival of patients treated for 
      advanced non small cell lung cancer (NSCLC). PATIENTS AND METHODS: We studied 158 
      patients with histological diagnosis of NSCLC (stage III/IV). Combined 
      chemoradiotherapy was used in stage III disease (without pleural effusion), 
      whereas chemotherapy only was used in stage III (with pleural effusion) as well 
      as in stage IV disease. Immunohistochemical analysis of NSE expression was 
      determined using antibodies to NSE (DAKO, Den). One- and 2-year overall survival 
      were assessed. RESULTS: 45 (28.5%) patients had positive NSE expression. The most 
      frequent NSE expression was seen in 6/9 (66.7%) patients with large cell 
      carcinoma and in 23/50 (46%) with adenocarcinoma. One- and 2-year survival rates 
      were 70% and 30% in the group of patients with positive NSE expression compared 
      to 26% and 3% in the group with negative NSE expression (p=0.000). The median 
      survival time was 16.4 vs. 11.4 months in the groups of patients with and without 
      NSE expression, respectively (p < 0.001). One-and 2-year survival rate was higher 
      in NSCLC patients with more than 50% of NSE positive cancer cells (p=0.0004 and 
      0.000, respectively). CONCLUSION: A total of 28.5% of advanced NSCLC patients had 
      positive NSE expression. Median 1- and 2-year survival time was significantly 
      longer in patients with positive NSE expression.
FAU - Petrovic, M
AU  - Petrovic M
AD  - Department of Pulmonology, Medical Faculty, University of Kragujevac, Serbia. 
      drmarinapetrovic@yahoo.com
FAU - Tomic, I
AU  - Tomic I
FAU - Plavec, G
AU  - Plavec G
FAU - Ilic, S
AU  - Ilic S
FAU - Ilic, N
AU  - Ilic N
FAU - Baskic, D
AU  - Baskic D
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - EC 4.2.1.11 (Phosphopyruvate Hydratase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/*enzymology/mortality
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*enzymology/mortality
MH  - Male
MH  - Middle Aged
MH  - Phosphopyruvate Hydratase/*analysis
MH  - Prognosis
MH  - Survival Rate
EDAT- 2008/04/12 09:00
MHDA- 2008/06/25 09:00
CRDT- 2008/04/12 09:00
PHST- 2008/04/12 09:00 [pubmed]
PHST- 2008/06/25 09:00 [medline]
PHST- 2008/04/12 09:00 [entrez]
PST - ppublish
SO  - J BUON. 2008 Jan-Mar;13(1):93-6.